Developmental exposure to chlorpyrifos elicits sex-selective alterations of serotonergic synaptic function in adulthood: critical periods and regional selectivity for effects on the serotonin transporter, receptor subtypes, and cell signaling.

Publisher: National Institute of Environmental Health Sciences Country of Publication: United States NLM ID: 0330411 Publication Model: Print Cited Medium: Print ISSN: 0091-6765 (Print) Linking ISSN: 00916765 NLM ISO Abbreviation: Environ Health Perspect Subsets: MEDLINE

Original Publication: Research Triangle Park, N. C. National Institute of Environmental Health Sciences.

Membrane Transport Proteins* ; Nerve Tissue Proteins* ; Prenatal Exposure Delayed Effects*; Central Nervous System/*embryology ; Chlorpyrifos/*toxicity ; Insecticides/*toxicity ; Receptors, Serotonin/*drug effects ; Receptors, Serotonin/*physiology ; Signal Transduction/*drug effects; Animals ; Carrier Proteins/metabolism ; Carrier Proteins/pharmacology ; Cell Differentiation ; Central Nervous System/drug effects ; Female ; Membrane Glycoproteins/metabolism ; Membrane Glycoproteins/pharmacology ; Pregnancy ; Rats ; Rats, Sprague-Dawley ; Serotonin Plasma Membrane Transport Proteins ; Synapses

During brain development, serotonin (5HT) provides essential neurotrophic signals, and in earlier work, we found that developmental exposure to chlorpyrifos (CPF) elicits short-term changes in 5HT systems. In the present study, we evaluated the effects in adulthood after CPF exposures from the neural tube stage [gestational days (GD) 9-12] and the late gestational period (GD17-20) through postnatal neuronal differentiation and synaptogenesis [postnatal days (PN) 1-4 and 11-14], using treatments below the threshold for systemic toxicity. With exposure on GD9-12, CPF elicited global elevations in 5HT1A and 5HT2 receptors and in the 5HT presynaptic transporter. The GD17-20 treatment elicited larger effects that displayed selectivity for regions with 5HT nerve terminals and that were preferential for males. Although similar receptor up-regulation was seen after PN1-4 exposure, the effects were larger in regions with 5HT cell bodies; in addition, the presynaptic transporter was down-regulated in the nerve terminal zones of females. The PN11-14 exposure had much smaller effects on receptors but still elicited transporter suppression with the same regional and sex selectivity. Although CPF exposure on GD17-20, PN1-4, or PN11-14 altered the ability of 5HT to modulate adenylyl cyclase, this change did not correspond with the effects on 5HT receptors, suggesting an additional set of effects on proteins that transduce the 5HT signal. Our results indicate that CPF elicits long-lasting changes in 5HT receptors, the presynaptic 5HT transporter, and 5HT-mediated signal transduction after exposure in discrete developmental windows that range from the neural tube stage through synaptogenesis. These effects are likely to contribute to neurobehavioral teratology of CPF.

Comment in: Environ Health Perspect. 2004 Feb;112(2):A112-3. (PMID: 14959713)

Pharmacol Toxicol. 2001 Oct;89(4):195-200. (PMID: 11881970)
Brain Res Dev Brain Res. 2002 Feb 28;133(2):151-61. (PMID: 11882345)
Toxicol Appl Pharmacol. 2002 Feb 15;179(1):1-12. (PMID: 11884232)
Eur J Pediatr. 2002 Aug;161(8):445-8. (PMID: 12172830)
Brain Res. 2002 Oct 4;951(2):280-92. (PMID: 12270507)
Environ Health Perspect. 2002 Nov;110(11):1097-103. (PMID: 12417480)
Am J Epidemiol. 2002 Nov 15;156(10):954-61. (PMID: 12419768)
Neurotoxicology. 2002 Oct;23(4-5):537-44. (PMID: 12428726)
Neurotoxicol Teratol. 2002 Nov-Dec;24(6):733-41. (PMID: 12460655)
Toxicology. 2002 Dec 27;181-182:23-33. (PMID: 12505280)
Environ Health Perspect. 2003 Mar;111(3):297-303. (PMID: 12611658)
Drug Metab Dispos. 2003 Apr;31(4):384-91. (PMID: 12642463)
Brain Res Bull. 1997;43(2):179-89. (PMID: 9222531)
Brain Res Dev Brain Res. 1992 Aug 21;68(2):233-9. (PMID: 1394969)
Eur Neuropsychopharmacol. 1993 Dec;3(4):463-75. (PMID: 7906577)
J Pharmacol Exp Ther. 1994 Apr;269(1):329-35. (PMID: 7513360)
Psychoneuroendocrinology. 1994;19(5-7):415-27. (PMID: 7938343)
Toxicol Appl Pharmacol. 1995 Sep;134(1):53-62. (PMID: 7545834)
Neurotoxicology. 1995 Summer;16(2):281-90. (PMID: 7566687)
Brain Res Bull. 1996;39(1):49-55. (PMID: 8846108)
Acta Neurobiol Exp (Wars). 1996;56(2):619-36. (PMID: 8768313)
J Mol Cell Cardiol. 1997 Feb;29(2):603-15. (PMID: 9140819)
Brain Res Bull. 1998;45(2):143-7. (PMID: 9443830)
Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1038-43. (PMID: 9448281)
Brain Res Dev Brain Res. 1997 Dec 19;104(1-2):209-13. (PMID: 9466725)
Toxicol Appl Pharmacol. 1998 Mar;149(1):107-19. (PMID: 9512733)
Toxicol Sci. 1998 Jan;41(1):8-20. (PMID: 9520337)
Brain Res Dev Brain Res. 1998 Jun 15;108(1-2):39-45. (PMID: 9693782)
Toxicol Appl Pharmacol. 1998 Jul;151(1):182-91. (PMID: 9705902)
J Neurosci. 1998 Sep 15;18(18):7394-401. (PMID: 9736659)
Toxicol Appl Pharmacol. 1998 Sep;152(1):56-65. (PMID: 9772200)
Toxicol Lett. 1998 Sep 15;98(3):139-46. (PMID: 9788582)
Brain Res Dev Brain Res. 1999 Mar 12;113(1-2):1-12. (PMID: 10064868)
J Pharmacol Exp Ther. 1999 Apr;289(1):334-45. (PMID: 10087022)
J Mol Cell Cardiol. 1999 Feb;31(2):413-23. (PMID: 10093053)
Circulation. 1999 Mar 30;99(12):1618-22. (PMID: 10096940)
J Toxicol Environ Health B Crit Rev. 1999 Apr-Jun;2(2):161-81. (PMID: 10230392)
Brain Res. 1999 May 22;829(1-2):39-45. (PMID: 10350528)
Environ Health Perspect. 1999 Feb;107 Suppl 1:71-80. (PMID: 10229709)
Environ Health Perspect. 1999 Jun;107 Suppl 3:431-7. (PMID: 10346991)
Brain Res Dev Brain Res. 1999 Aug 5;116(1):9-20. (PMID: 10446342)
J Neurobiol. 1999 Sep 15;40(4):602-19. (PMID: 10453059)
Neuropharmacology. 1999 Aug;38(8):1083-152. (PMID: 10462127)
Br J Pharmacol. 1999 Aug;127(8):1751-64. (PMID: 10482904)
J Neuroendocrinol. 2003 Jun;15(6):622-7. (PMID: 12716414)
Environ Health Perspect. 2003 Nov;111(14):1736-43. (PMID: 14594624)
Environ Health Perspect. 2003 Dec;111(16):1871-6. (PMID: 14644659)
Mol Pharmacol. 1982 Mar;21(2):301-14. (PMID: 7099138)
Prog Clin Biol Res. 1985;163C:375-80. (PMID: 2859601)
Adv Cyclic Nucleotide Protein Phosphorylation Res. 1986;20:1-150. (PMID: 3028083)
Prog Brain Res. 1988;73:335-48. (PMID: 3047802)
Life Sci. 1990;47(17):1561-7. (PMID: 2174490)
Toxicology. 1991;68(1):51-61. (PMID: 1714639)
Biol Neonate. 1991;60(2):127-36. (PMID: 1657219)
Psychiatry Res. 1991 Aug;38(2):97-104. (PMID: 1836639)
Pharmacol Rev. 1991 Dec;43(4):553-61. (PMID: 1663620)
Toxicology. 1992;73(1):35-43. (PMID: 1375401)
Eur J Pharmacol. 1992 Mar 12;225(3):273-4. (PMID: 1325368)
Trends Neurosci. 1997 Jun;20(6):269-74. (PMID: 9185309)
Toxicol Appl Pharmacol. 1997 Jul;145(1):158-74. (PMID: 9221834)
Perspect Dev Neurobiol. 1998;5(4):323-35. (PMID: 10533523)
Perspect Dev Neurobiol. 1998;5(4):389-99. (PMID: 10533527)
Toxicol Appl Pharmacol. 1999 Nov 1;160(3):217-30. (PMID: 10544056)
Hum Exp Toxicol. 1999 Oct;18(10):598-601. (PMID: 10557009)
Brain Res. 1999 Nov 13;847(1):90-7. (PMID: 10564740)
Neurotoxicology. 2000 Feb-Apr;21(1-2):15-36. (PMID: 10794382)
Toxicol In Vitro. 2000 Jun;14(3):227-34. (PMID: 10806373)
Brain Res Dev Brain Res. 2000 May 11;121(1):19-27. (PMID: 10837889)
Environ Health Perspect. 2000 Jun;108(6):A262-7. (PMID: 10856040)
Toxicol Appl Pharmacol. 2000 Jun 15;165(3):175-83. (PMID: 10873710)
Brain Res. 2000 Sep 29;878(1-2):119-26. (PMID: 10996142)
Brain Res. 2001 Feb 9;891(1-2):54-68. (PMID: 11164809)
Toxicol Lett. 2001 Mar 31;120(1-3):343-51. (PMID: 11323193)
Mol Genet Metab. 2001 May;73(1):11-7. (PMID: 11350178)
Brain Res. 2001 Jun 1;902(2):229-43. (PMID: 11384617)
Brain Res Dev Brain Res. 2001 Sep 23;130(1):65-72. (PMID: 11557094)
Brain Res Dev Brain Res. 2001 Sep 23;130(1):83-9. (PMID: 11557096)
Brain Res. 2001 Sep 28;914(1-2):166-78. (PMID: 11578609)
Environ Health Perspect. 2001 Sep;109(9):909-13. (PMID: 11673119)
Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):113-25. (PMID: 11718842)
Arch Toxicol. 2001 Oct;75(8):480-6. (PMID: 11757672)
Brain Res Bull. 2001 Nov 15;56(5):413-24. (PMID: 11750787)
Neurotoxicology. 2001 Dec;22(6):811-7. (PMID: 11829414)
J Biochem Mol Toxicol. 2001;15(5):263-9. (PMID: 11835623)
Arch Toxicol. 2002 Jan;75(11-12):676-84. (PMID: 11876500)

ES10356 United States ES NIEHS NIH HHS; ES10387 United States ES NIEHS NIH HHS

0 (Carrier Proteins)
0 (Insecticides)
0 (Membrane Glycoproteins)
0 (Membrane Transport Proteins)
0 (Nerve Tissue Proteins)
0 (Receptors, Serotonin)
0 (Serotonin Plasma Membrane Transport Proteins)
0 (Slc6a4 protein, rat)
JCS58I644W (Chlorpyrifos)

Date Created: 20040203 Date Completed: 20040506 Latest Revision: 20181113

20221213

PMC1241823

10.1289/ehp.6713

14754568